References
- DeAngelis L M. Primary central nervous system lymphoma: a curable brain tumor. J Clin Oncol 2003; 21: 4471–4473
- Sarkar C, Sharma M C, Deb P, Singh R, Santosh V, Shankar S H. Primary central nervous system lymphoma—a hospital based study of incidence and clinicopathological features from India (1980 – 2003). J Neurooncol 2005; 71: 199–204
- Pels H, Schmidt-Wolf I G, Glasmacher A, Kleinschmidt R, Oehring B, Fischer H P, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489–4495
- Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002; 59: 213–216
- Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Geming U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89: 753–754
- Thomas D A, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569–1580
- Maloney D G. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines. J Clin Oncol 2005; 23: 6421–6428
- Harjunpaa A, Wiklund T, Collan J, Janes R, Rosenberg J, Lee D, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001; 42: 731–738
- Ruhstaller T W, Amsler U, Cerny T. Rituximab: Active treatment of central nervous system involvement by non-Hodgkin's lymphoma?. Ann Oncol 2000; 11: 374–375
- Pels H, Schulz H, Schlegel U, Engert A. Treatment of CNS lymphoma with the anti-CD20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003; 26: 351–354
- Rubenstein J L, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466–468